VANCOUVER, British Columbia, Sept. 27, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce it has applied for patent protection of new compositions of 2-bromo-LSD for its use in the…


Previous articleDelix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders
Next articlePsychedelic Research Bulletin: July & August 2021